Dr. Rahul Gaurav is a Scientist with around a decade of research job experience in Paris, France. He works with the Movement, Investigations and Therapeutics (MOV'IT) team and the Center for NeuroImaging Research (CENIR) at the Paris Brain Institute (ICM - Institut du Cerveau), Sorbonne Université, INSERM U1127, CNRS UMR 7225, Pitié-Salpêtrière Hospital, France.
He holds a Doctorate in Neuroscience and Neuroimaging from the Doctoral School of Brain, Behavior and Cognition (ED 158 3C) of Sorbonne University, a Master of Science degree (Electronics Engineering, 2 years), and a Bachelor of Technology degree (Electrical Engineering, 4 years). He has authored and co-authored more than 30 research papers in peer-reviewed scientific conferences and journals.
Dr. Gaurav is an active member of international scientific organizations such as the Organization of Human Brain Mapping (OHBM), the International Society for Magnetic Resonance in Medicine (ISMRM), and the Society for Neuroscience (SfN). He is a regular contributor to the International Parkinson and Movement Disorder Society (MDS) of the United States of America.
He is also the Social Media and Communication Manager of the Organization of Human Brain Mapping (OHBM) Special Interest Group.
In general, Dr. Gaurav is interested in a much deeper understanding of how the human mind and brain work and is driven to solve the world’s biggest challenges through innovation.
- Neuroscience (mostly clinical)
- Movement Disorders; Neurodegenerative Diseases (Parkinson’s Disease, Atypical Parkinsonian Syndromes such as PSP, MSA, and Prodromal such as Isolated REM Sleep Behavior Disorder, iRBD)
- Neuroimaging (mostly structural MRI)
- Artificial Intelligence using Deep Learning
- Variations in locus coeruleus in atypical Parkinsonian syndromes.
- Neuromelanin changes in asymptomatic carriers of LRRK2 genes and risk of Parkinson's disease.
- Substantia Nigra neuromelanin content in substantia nigra in atypical Parkinsonian syndromes.
- Iron overload in substantia nigra and subthalamic nucleus in iRBD and idiopathic Parkinson’s disease patients using Quantitative Susceptibility Mapping (QSM) and R2* mapping.
- Longitudinal substantia nigra neuromelanin changes in iRBD and Parkinson’s disease patients using multimodal MRI to monitor disease progression.
- MRI biomarker of neuromelanin using convolutional neural network.